Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXAGEN INC.XGN · Entity 935 | Director | June 09, 2023 | June 13, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXAGEN INC.
Report date June 09, 2023 · Filed June 13, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.13 · Expires 2023-06-08 | Direct | 9,000 |
Reported balance
After 2023-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-09 · Grant · Acquired 9,000 · Balance 9,000 F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2023 Filed Jun 13, 2023 20:36 UTC | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 9,000 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0001274737-23-000062 · wf-form4_168668855957603.xml · derivative · entry 1 PALLARES EBETUEL · CIK 0001614597 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2023-06-08 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 12:33 UTC | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 9,000 | $0.00 Strike: $5.25 | $0.00 |
DisclosureSEC source: 0001274737-22-000045 · wf-form4_165581481042927.xml · derivative · entry 1 PALLARES EBETUEL · CIK 0001614597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 12:39 UTC | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 9,000 | $0.00 Strike: $16.41 | $0.00 |
DisclosureSEC source: 0001274737-21-000078 · wf-form4_162427916173757.xml · derivative · entry 1 PALLARES EBETUEL · CIK 0001614597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2031-06-16 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 18, 2020 Filed Jul 2, 2020 12:42 UTC | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 9,000 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001274737-20-000063 · wf-form4_159369365100589.xml · derivative · entry 1 PALLARES EBETUEL · CIK 0001614597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| April 13, 2020 Filed Apr 16, 2020 00:34 UTC | EXAGEN INC. XGN · Entity 935 | OtherCommon Stock | 1,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024575 · doc4.xml · nonDerivative · entry 2 PALLARES EBETUEL · CIK 0001614597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,185 F3 · kind: Dr. Pallares received shares distributed by PCM on a pro rata basis for no consideration to its limited partners. Read SEC document |
| April 13, 2020 Filed Apr 16, 2020 00:34 UTC | EXAGEN INC. XGN · Entity 935 | OtherCommon Stock | 144,033 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024575 · doc4.xml · nonDerivative · entry 1 PALLARES EBETUEL · CIK 0001614597 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: PCM/Exagen, L.P. (PCM) distributed 144,033 shares of Common Stock of the Issuer to its limited partners on a pro rata basis, for no consideration. F2 · ownership.nature: The shares reported on this form are held of record by PCM/Exgen, L.P. Ebetuel Palleres is co-manager of PCM. As a result, each of PCM and Dr. Palleres may be deemed to share beneficial ownership of the shares held of record by PCM. Read SEC document |
| March 11, 2020 Filed Mar 27, 2020 22:07 UTC | EXAGEN INC. XGN · Entity 935 | Exercise / conversionWarrants · Derivative | 2,265 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001209191-20-021486 · doc4.xml · derivative · entry 6 PALLARES EBETUEL · CIK 0001614597 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,265 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The warrants are currently exercisable and will expire on March 31, 2026. F4 · derivative.expiration_date: The warrants are currently exercisable and will expire on March 31, 2026. F1 · ownership.nature: The shares reported on this form are held of record by PCM/Exagen, L.P. ("PCM"). Ebetuel Pallares is a co-manager of PCM. As a result, each of PCM and Dr. Pallares may be deemed to share beneficial ownership of the shares held of record by PCM. Read SEC document |
| March 11, 2020 Filed Mar 27, 2020 22:07 UTC | EXAGEN INC. XGN · Entity 935 | Exercise / conversionWarrants · Derivative | 22,427 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001209191-20-021486 · doc4.xml · derivative · entry 5 PALLARES EBETUEL · CIK 0001614597 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 22,427 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The warrants are currently exercisable and will expire on January 19, 2026. F3 · derivative.expiration_date: The warrants are currently exercisable and will expire on January 19, 2026. F1 · ownership.nature: The shares reported on this form are held of record by PCM/Exagen, L.P. ("PCM"). Ebetuel Pallares is a co-manager of PCM. As a result, each of PCM and Dr. Pallares may be deemed to share beneficial ownership of the shares held of record by PCM. Read SEC document |
| March 11, 2020 Filed Mar 27, 2020 22:07 UTC | EXAGEN INC. XGN · Entity 935 | Tax withholdingCommon Stock | 214 | $19.51 | $4,174.50 |
DisclosureSEC source: 0001209191-20-021486 · doc4.xml · nonDerivative · entry 4 PALLARES EBETUEL · CIK 0001614597 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 144,033 F3 · shares: The warrants are currently exercisable and will expire on January 19, 2026. F1 · ownership.nature: The shares reported on this form are held of record by PCM/Exagen, L.P. ("PCM"). Ebetuel Pallares is a co-manager of PCM. As a result, each of PCM and Dr. Pallares may be deemed to share beneficial ownership of the shares held of record by PCM. Read SEC document |
| March 11, 2020 Filed Mar 27, 2020 22:07 UTC | EXAGEN INC. XGN · Entity 935 | Exercise / conversionCommon Stock | 2,265 | $1.84 | $4,167.60 |
DisclosureSEC source: 0001209191-20-021486 · doc4.xml · nonDerivative · entry 3 PALLARES EBETUEL · CIK 0001614597 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 144,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares reported on this form are held of record by PCM/Exagen, L.P. ("PCM"). Ebetuel Pallares is a co-manager of PCM. As a result, each of PCM and Dr. Pallares may be deemed to share beneficial ownership of the shares held of record by PCM. Read SEC document |
| March 11, 2020 Filed Mar 27, 2020 22:07 UTC | EXAGEN INC. XGN · Entity 935 | Tax withholdingCommon Stock | 2,112 | $19.51 | $41,198.78 |
DisclosureSEC source: 0001209191-20-021486 · doc4.xml · nonDerivative · entry 2 PALLARES EBETUEL · CIK 0001614597 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 141,982 F2 · shares: Represents the cashless net exercise of a warrant through the surrender of shares to the Issuer based on a fair market value of $19.507 per share, as determined by the average closing price of the Issuer's common stock for the ten trading days immediately preceding the date of exercise. F1 · ownership.nature: The shares reported on this form are held of record by PCM/Exagen, L.P. ("PCM"). Ebetuel Pallares is a co-manager of PCM. As a result, each of PCM and Dr. Pallares may be deemed to share beneficial ownership of the shares held of record by PCM. Read SEC document |
| March 11, 2020 Filed Mar 27, 2020 22:07 UTC | EXAGEN INC. XGN · Entity 935 | Exercise / conversionCommon Stock | 22,427 | $1.84 | $41,265.68 |
DisclosureSEC source: 0001209191-20-021486 · doc4.xml · nonDerivative · entry 1 PALLARES EBETUEL · CIK 0001614597 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 144,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares reported on this form are held of record by PCM/Exagen, L.P. ("PCM"). Ebetuel Pallares is a co-manager of PCM. As a result, each of PCM and Dr. Pallares may be deemed to share beneficial ownership of the shares held of record by PCM. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 01:45 UTC | EXAGEN INC. XGN · Entity 935 | ConversionSeries F Redeemable Convertible Preferred Stock · Derivative | 7,970,686 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-024082 · doc4.xml · derivative · entry 6 PALLARES EBETUEL · CIK 0001614597 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 43,405 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series F Redeemable Convertible Preferred Stock ("Series F") is convertible into the Issuer's Common Stock on a 183.635-for-one basis at the holder's election and has no expiration date. The Series F automatically converted into Common Stock upon the closing of the Issuer's initial public offering. F5 · price: The Series F Redeemable Convertible Preferred Stock ("Series F") is convertible into the Issuer's Common Stock on a 183.635-for-one basis at the holder's election and has no expiration date. The Series F automatically converted into Common Stock upon the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: The Series F Redeemable Convertible Preferred Stock ("Series F") is convertible into the Issuer's Common Stock on a 183.635-for-one basis at the holder's election and has no expiration date. The Series F automatically converted into Common Stock upon the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: The Series F Redeemable Convertible Preferred Stock ("Series F") is convertible into the Issuer's Common Stock on a 183.635-for-one basis at the holder's election and has no expiration date. The Series F automatically converted into Common Stock upon the closing of the Issuer's initial public offering. F1 · ownership.nature: The shares reported on this form are held of record by PCM/Exagen, L.P. ("PCM"). Ebetuel Pallares is a co-manager of PCM. As a result, each of PCM and Dr. Pallares may be deemed to share beneficial ownership of the shares held of record by PCM. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 01:45 UTC | EXAGEN INC. XGN · Entity 935 | ConversionSeries E Redeemable Convertible Preferred Stock · Derivative | 4,423,371 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-024082 · doc4.xml · derivative · entry 5 PALLARES EBETUEL · CIK 0001614597 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 77,204 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series E Redeemable Convertible Preferred Stock (the "Series E") is convertible into the Issuer's Common Stock on a 57.294-for-one basis at the holder's election and has no expiration date. The Series E automatically converted into Common Stock upon the closing of the Issuer's initial public offering. F4 · price: The Series E Redeemable Convertible Preferred Stock (the "Series E") is convertible into the Issuer's Common Stock on a 57.294-for-one basis at the holder's election and has no expiration date. The Series E automatically converted into Common Stock upon the closing of the Issuer's initial public offering. F4 · derivative.exercise_date: The Series E Redeemable Convertible Preferred Stock (the "Series E") is convertible into the Issuer's Common Stock on a 57.294-for-one basis at the holder's election and has no expiration date. The Series E automatically converted into Common Stock upon the closing of the Issuer's initial public offering. F4 · derivative.expiration_date: The Series E Redeemable Convertible Preferred Stock (the "Series E") is convertible into the Issuer's Common Stock on a 57.294-for-one basis at the holder's election and has no expiration date. The Series E automatically converted into Common Stock upon the closing of the Issuer's initial public offering. F1 · ownership.nature: The shares reported on this form are held of record by PCM/Exagen, L.P. ("PCM"). Ebetuel Pallares is a co-manager of PCM. As a result, each of PCM and Dr. Pallares may be deemed to share beneficial ownership of the shares held of record by PCM. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 01:45 UTC | EXAGEN INC. XGN · Entity 935 | ConversionCommon Stock | 120,609 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-024082 · doc4.xml · nonDerivative · entry 3 PALLARES EBETUEL · CIK 0001614597 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 121,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares reported on this form are held of record by PCM/Exagen, L.P. ("PCM"). Ebetuel Pallares is a co-manager of PCM. As a result, each of PCM and Dr. Pallares may be deemed to share beneficial ownership of the shares held of record by PCM. Read SEC document |
| September 19, 2019 Filed Sep 24, 2019 01:45 UTC | EXAGEN INC. XGN · Entity 935 | OtherWarrants · Derivative | 3,839 | $14.32 Strike: $14.32 | $54,987.92 |
DisclosureSEC source: 0000899243-19-024082 · doc4.xml · derivative · entry 4 PALLARES EBETUEL · CIK 0001614597 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,839 shares Expires not disclosed F2 · derivative.exercise_date: The warrants are currently exercisable and will terminate upon closing of the Issuer's initial public offering. F2 · derivative.expiration_date: The warrants are currently exercisable and will terminate upon closing of the Issuer's initial public offering. F3 · derivative.underlying: Represents warrants that previously entitled the holders to purchase Series E Redeemable Convertible Preferred Stock, which, pursuant to their terms, were settled in shares of the Issuer's Common Stock. F1 · ownership.nature: The shares reported on this form are held of record by PCM/Exagen, L.P. ("PCM"). Ebetuel Pallares is a co-manager of PCM. As a result, each of PCM and Dr. Pallares may be deemed to share beneficial ownership of the shares held of record by PCM. Read SEC document |
| September 19, 2019 Filed Sep 24, 2019 01:45 UTC | EXAGEN INC. XGN · Entity 935 | Tax withholdingCommon Stock | 2,960 | $18.58 | $54,996.80 |
DisclosureSEC source: 0000899243-19-024082 · doc4.xml · nonDerivative · entry 2 PALLARES EBETUEL · CIK 0001614597 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,058 F1 · ownership.nature: The shares reported on this form are held of record by PCM/Exagen, L.P. ("PCM"). Ebetuel Pallares is a co-manager of PCM. As a result, each of PCM and Dr. Pallares may be deemed to share beneficial ownership of the shares held of record by PCM. Read SEC document |
| September 19, 2019 Filed Sep 24, 2019 01:45 UTC | EXAGEN INC. XGN · Entity 935 | OtherCommon Stock | 3,839 | $14.32 | $54,987.92 |
DisclosureSEC source: 0000899243-19-024082 · doc4.xml · nonDerivative · entry 1 PALLARES EBETUEL · CIK 0001614597 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,018 F1 · ownership.nature: The shares reported on this form are held of record by PCM/Exagen, L.P. ("PCM"). Ebetuel Pallares is a co-manager of PCM. As a result, each of PCM and Dr. Pallares may be deemed to share beneficial ownership of the shares held of record by PCM. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.